Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Emerging Therapies For Newly…
Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses Outcomes From The ALCYONE Study. At The 60th ASH…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses The Development Of LCAR-B38M. At The 60th ASH Annual Meeting…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study.…
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Use Of…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At…
Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Venetoclax In Treatment Of…
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses…
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope,…
Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses The Role Of Advanced Practice Practitioners. At…
David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Anti-BCMA CAR-T Cell Therapy For MM Patients.…
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Management Of Common…
Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Effectiveness Of Anti-BCMA CAR-T Cell Therapy. At The 60th ASH Annual Meeting on…
Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Outcomes Of The POLLUX And CASTOR Studies. At The 60th ASH Annual Meeting…
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
James McClosky, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Using Newly FDA…
Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Outcomes Of CA204-142 In…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Reliability…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Will CAR-T Therapies Be Expanded Into Solid Tumors. At The…
Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Outcomes From The iLLUMINATE Trial. At The 60th ASH Annual Meeting…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses…
Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Outcomes…
Nizar Bahlis, MD University of Calgary, Calgary, discusses The Future Of Anti-BCMA CAR-T Cell Therapy In MM. At The 60th…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on…
Nizar Bahlis, MD University of Calgary, Calgary, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on…
Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Study Examining The…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Current Maintenance Regimens In MM. At The 60th…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses How Gilteritinib Fits Into…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope,…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Role Of…
Chadi Nabhan, MD, MBA VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses What Is Being Done To Prevent Oncologist…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses How City…
Jeff Sharman, MD Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Julie Vose, MD Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Does Polatuzumab Improve…
Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Addition Of Daratumumab To Revlimid/Dexamethasone In MM. At The…
Rod A. Humerickhouse, MD, PhD Group Project Leader, Oncology Development, AbbVie, discusses Recent Advancements In The Treatment Of CLL. At…
Sen Zhuang, MD, PhD VP, Oncology Clinical Research, Janssen, discusses How LCAR-838M May Impact The Treatment Of MM. At The…
Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Future Of…
Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Outcomes Of The POLLUX And CASTOR Studies. At…
Swaminathan P. Iyer, MD Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Management Of Toxicity With CAR-T Therapies. At The 60th ASH…
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses The Role Of Allogeneic Transplantation…
Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, discusses Results Of…
Andrzej Jakubowiak, MD Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, discusses GRIFFIN Study Outcomes. At The…
Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Recent Advancements In The Treatment Of CLL. At The 60th ASH…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Discussing The POLLUX And CASTOR Studies. At…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses The Future Of Anti-BCMA CAR-T Cell Therapy.…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Outcomes Of The GRIFFIN Study. At The…
Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, ?Center for Discovery and Innovation, Hackensack University, discusses Age-Associated Aberrant…
Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center, discusses The Role…
Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Discussing The CASTOR Trial Presented At ASH 2018. At…
Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Maintenance Regimens For Multiple…
Tatyana Feldman, MD Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Unmet Needs In Peripheral…
Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses The LEAP Consortium Research Outcomes. At…
Samer Khaled, MD Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses Treatment Of Acute…
Robert Rifkin, MD Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers Discusses Does Anti-BCMA CAR-T Cell Therapy…
Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center discusses Are CAR-T Therapies…
Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center Discusses The Necessity…
Swaminathan Padmanabhan Iyer, MD Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center discusses Game Changing ECHELON-2 Study For…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center Discusses Using CAR-T Therapies In Leukemia & Lymphoma. At The 60th…
David Siegel, MD Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center Discusses Results Of MM014 Study. At The 60th…
Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions Discusses Two Sided Payment Agreements & The Risks…
Andrzej Jakubowiak, MD, PhD Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center discusses Multiple Myeloma Maintenance Regimens.…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine Discusses Data…
Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses CAR-T Therapies…
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers Discusses Research…
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
James McCloskey, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center Discusses Application Of The…
Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center Discusses ZUMA-1 Two-Year Follow-Up…
Rafael Fonseca, MD Hematologist, Mayo Clinic Discusses Maintenance Regimens For MM At The 60th ASH Annual Meeting on Dec 1,…
Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Discusses AML Genetic Testing Prior…
Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute Discusses…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen Discusses Anti-BCMA CAR-T Cell Therapy In MM. At The…
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+…
Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center Discusses The Microboime…
Habte Yimer, MD, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology Discusses Lyra Trial In Newly Diagnosed MM At…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, Discusses LCAR-838M Study In Relapsed/Refractory MM At The 60th ASH Annual…
Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, Discusses Leukemia-Initiating Metabolic…
Jasmine Zain, MD Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope…
Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th…
Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses LEAP Consortium In Pediatric Acute Leukemia…
Rod A. Humerickhouse, M.D., PhD Group Project Leader, Oncology Development, AbbVie Discusses Venetoclax In Treatment Of MM At The 60th…
Nizar Bahlis, M.D. University of Calgary, Calgary Discusses ASH 2018: CASTOR & POLLUX Studies Impact At The 60th ASH Annual…
Steven Chang, M.D., M.S. Urologic Oncologist and Health Service Researcher at Brigham and Women’s Hospital discusses Should We Be Doing…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Why Not Use Bulk RNA Sequencing…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses The Future Of Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Single Cell RNA Sequencing In Kidney…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses How To Deal With Intra &…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Understanding & Using Combo Approaches With…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progressive Disease After Receiving CAR T…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progression Of Disease & Treatment At…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Designing Prospective Trials At The 60th…
Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Clinical Trials For The Future At…
Dr. J.J. Kiladjian ASH 2018 Headline Research Studies
Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys in Patients with Myelofibrosis
Real World Risk Assessment and Treatment of patients with Myelofibrosis at Community Oncology Practices in the U.S.
Koen Van Besien, M.D. Director of the Stem Cell Transplant Program, Professor of Medicine at Weill Cornell Medical College Discusses…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College…
Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses What To Do With A Patient With Advanced CMML?…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Lenalidomide In High Risk MDS Patients at Lymphoma &…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Hypomethylating Drugs & Mutations In MDS at Lymphoma &…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses How Long To Treat With Azacitidine at Lymphoma &…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Whats On The Horizon For Myeloma at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Triplet Drug Combo at Lymphoma & Myeloma on…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses The Role Of Ixazomib In Front Line Therapy…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Renal Insufficiency At Time Of Diagnosis at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses MRD Not Ready Outside Clinicial Trials at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Front Line Therapy Of Myeloma at Lymphoma &…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
Kanti Rai, M.D. Professor of medicine at The Karches Center for Oncology Research, The Feinstein Institute for Medical Research; director…
Samir Parekh, M.D. Associate Professor of medicine, hematology, medical oncology, and oncological sciences at the Icahn School of Medicine at…
Suzanne Lentzsch, M.D., PhD Associate Professor of Medicine & Director of the Multiple Myeloma and Amyloidosis Service at Columbia University…
Shaji Kumar, M.D. Professor of Medicine Mayo Clinic College of Medicine In Rochester, Minnesota Discusses Allogeneic Stem Cell Transplant: Multiple…
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in…
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ELIQUIS(Apixaban) In Non Cancer Setting…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial: Upper Extremity &…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Overall Event Rates…
Adam Binder, M.D. Assistant Professor at Thomas Jefferson University Hospital Discusses Approving Vancomycin With Neutropenic Fever Patients At The 60th…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Metabolic Reprogramming At The 60th…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses AstraZeneca The Leader In Hematology At The 60th ASH…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Key Clinical Data At The 60th ASH Annual…
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Where Does…
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Lyra: Front…
Shyamala Navada, M.D. Assistant Professor at Mount Sinai Health System Discusses Oral Rigosertib With Standard Dose Azacitidine At The 60th…
Dr. Ashutosh Tewari discusses the nature of genetic difference and aggressiveness among African-Ameican men
Dr. Nihal Mohamed discusses research on active surveillance among high risk populations, particularly African-American
Dr. Susan Slovin discusses the newly discovered Mo stage of prostate cancer
Dr. William Oh discusses the role of PARP inhibitors in treating prostate cancer
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Summary At The…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses The Future Of Daratumumab At The 60th ASH Annual Meeting on…
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses Daratumumab In A Primary Fractory Population At The 60th ASH Annual…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Rafael Fonseca, M.D. Clinical Investigator For The Damon Runyon Cancer Research Fund Discusses MAIA Study, AMG 420 Compound, KRD Transplant…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Dr. William Oh discusses the potential for immunotherapy in treating prostate cancer
Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Transfusion Independance With Hypomethylating agents At The 60th…
Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Is Patient Survival Based On Physician Experience At…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Trial follow Up At…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Therapy: Infection Rate &…
Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Whats Next For Isatuximab At The 60th ASH Annual Meeting on…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Value Of Dexamethasone At The 60th ASH Annual Meeting on Dec…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Phase 2 Study Isatuximab & Dexamethasone At The 60th ASH Annual…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual…
Dr. Susan Slovin discusses how the evolution of therapeutic treatment is occurring in advanced stage prostate cancer
The concept of Precision Therapy in Prostate Cancer treatment will need to rely more heavily on genetic testing
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the next steps for Ixazomib in Multiple Myeloma after…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses Duration of Maintenance and the Advantage to High Risk…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the results of the phase 3 study TOURMALINE-MM3. The…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Risk Of Developing (t-MDS) After Chemo & Radiation At The…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Reasoning Behind ALL As Second Cancer Studyy At The 60th…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses Next Step In Research For (t-MDS) At The 60th ASH…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses ALL As Second Cancer After Treatment, Explorative Study At The…
Sudipto Mukherjee M.D., hematology oncology physician at Cleveland Clinic Discusses (t-MDS) Research & Outcomes At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Ongoing Trials For CLL Patients At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Advances In New Cancer Regiments At The 60th ASH Annual Meeting…
Peter Turecek, PhD Senior Director R&D bei Shire Discusses iPATH Study At The 60th ASH Annual Meeting on Dec 1,…
Dr. Khorana M.D., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis…
Dr. Khorana M.D., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, CaseWestern Reserve University, the Sondra and Stephen Hardis…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Venetoclax & Carfilzomib Dose Escalation Study At The 60th ASH Annual…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Phase 3 MURANO Trial At The 60th ASH Annual Meeting on…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Benefits Of Venetoclax Studies At The 60th ASH Annual Meeting on…
Aaron Gerds, M.D., M.S. assistant professor of medicine in the Hematology and Medical Oncology department at the Cleveland Clinic Taussig…
Rajat Bannerji, MD, PhD Associate Professor of Medicine Division of Hematology Oncology Robert Wood Johnson Medical School Rutgers, The State…
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for…
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic…
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for…
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Neil E. Kay, M.D., Professor of Medicine at the Mayo Clinic College of Medicine and a Consultant in the Department…
Pinkal Desai, M.D., Assistant Professor of Medicine Weill Cornell Medical College, Cornell University And Assistant Attending Physician at the New…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Ken Anderson M.D., Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute…
Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity…
Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity…
Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr.…
Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr.…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Nurse Rita…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in RIn this presentation from the ‘R AML: Evaluating Emerging…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Earn CME: https://naccme.com/program/7311 In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…
Earn CME: https://naccme.com/program/7310 In this presentation from the ‘New and Emerging Agents in ALL and the Evolving Treatment Paradigm symposium,…